NASDAQ:KURA Kura Oncology (KURA) Stock Price, News & Analysis $5.81 +0.21 (+3.75%) Closing price 04:00 PM EasternExtended Trading$5.80 0.00 (-0.09%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Kura Oncology Stock (NASDAQ:KURA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kura Oncology alerts:Sign Up Key Stats Today's Range$5.65▼$6.0050-Day Range$5.55▼$6.9252-Week Range$5.41▼$23.48Volume1.55 million shsAverage Volume1.25 million shsMarket Capitalization$502.97 millionP/E RatioN/ADividend YieldN/APrice Target$24.50Consensus RatingModerate Buy Company Overview Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California. Read More Kura Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreKURA MarketRank™: Kura Oncology scored higher than 91% of companies evaluated by MarketBeat, and ranked 104th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingKura Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 10 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageKura Oncology has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Kura Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Kura Oncology are expected to grow in the coming year, from ($2.44) to ($1.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kura Oncology is -2.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kura Oncology is -2.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKura Oncology has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Kura Oncology's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.75% of the float of Kura Oncology has been sold short.Short Interest Ratio / Days to CoverKura Oncology has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Kura Oncology has recently decreased by 5.50%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKura Oncology does not currently pay a dividend.Dividend GrowthKura Oncology does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.76 Percentage of Shares Shorted9.75% of the float of Kura Oncology has been sold short.Short Interest Ratio / Days to CoverKura Oncology has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Kura Oncology has recently decreased by 5.50%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.43 News SentimentKura Oncology has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Kura Oncology this week, compared to 6 articles on an average week.Search InterestOnly 8 people have searched for KURA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Kura Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Kura Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,076.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Kura Oncology is held by insiders.Read more about Kura Oncology's insider trading history. Receive KURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address KURA Stock News HeadlinesAnalysts Set Kura Oncology, Inc. (NASDAQ:KURA) Target Price at $24.50June 26, 2025 | americanbankingnews.comKura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlookJune 15, 2025 | investing.comBanks aren’t ready for this altcoin—are you?In crypto, timing is everything. By the time the masses catch wind of this, the biggest gains could be ancient history. Are you ready to potentially change your financial future forever?July 2 at 2:00 AM | Crypto 101 Media (Ad)Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association CongressJune 12, 2025 | globenewswire.comLightning Round: 'Wait and see situation' with Papa John's, says Jim CramerJune 12, 2025 | msn.comKura Oncology Grants Stock Options To New Hires Under Inducement PlanJune 7, 2025 | nasdaq.comKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comASCO25: Kura’s Phase II ziftomenib results trigger NDA acceptance from FDAJune 3, 2025 | finance.yahoo.comSee More Headlines KURA Stock Analysis - Frequently Asked Questions How have KURA shares performed this year? Kura Oncology's stock was trading at $8.71 at the beginning of 2025. Since then, KURA stock has decreased by 33.3% and is now trading at $5.81. View the best growth stocks for 2025 here. How were Kura Oncology's earnings last quarter? Kura Oncology, Inc. (NASDAQ:KURA) posted its earnings results on Thursday, May, 1st. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.15. The firm had revenue of $14.11 million for the quarter, compared to the consensus estimate of $39.08 million. Read the conference call transcript. When did Kura Oncology's stock split? Shares of Kura Oncology reverse split before market open on Friday, October 18th 2024.The 1-35 reverse split was announced on Monday, October 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Kura Oncology? Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kura Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kura Oncology investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Walmart (WMT). Company Calendar Last Earnings5/01/2025Today7/02/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KURA CIK1422143 Webwww.kuraoncology.com Phone(858) 500-8800FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Stock Price Target$24.50 High Stock Price Target$40.00 Low Stock Price Target$10.00 Potential Upside/Downside+314.9%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($2.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$173.98 million Net MarginsN/A Pretax Margin-264.22% Return on Equity-43.62% Return on Assets-29.13% Debt Debt-to-Equity Ratio0.02 Current Ratio8.07 Quick Ratio8.07 Sales & Book Value Annual Sales$53.88 million Price / Sales9.49 Cash FlowN/A Price / Cash FlowN/A Book Value$5.32 per share Price / Book1.11Miscellaneous Outstanding Shares86,570,000Free Float81,034,000Market Cap$511.20 million OptionableOptionable Beta0.40 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:KURA) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kura Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.